Literature DB >> 11242115

Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia.

K Devriendt1, A S Kim, G Mathijs, S G Frints, M Schwartz, J J Van Den Oord, G E Verhoef, M A Boogaerts, J P Fryns, D You, M K Rosen, P Vandenberghe.   

Abstract

The Wiskott-Aldrich syndrome protein (WASP; encoded by the gene WAS) and its homologs are important regulators of the actin cytoskeleton, mediating communication between Rho-family GTPases and the actin nucleation/crosslinking factor, the Arp2/3 complex. Many WAS mutations impair cytoskeletal control in hematopoietic tissues, resulting in functional and developmental defects that define the X-linked Wiskott-Aldrich syndrome (WAS) and the related X-linked thrombocytopenia (XLT). These diseases seem to result from reduced WASP signaling, often through decreased transcription or translation of the gene. Here we describe a new disease, X-linked severe congenital neutropenia (XLN), caused by a novel L270P mutation in the region of WAS encoding the conserved GTPase binding domain (GBD). In vitro, the mutant protein is constitutively activated through disruption of an autoinhibitory domain in the wild-type protein, indicating that loss of WASP autoinhibition is a key event in XLN. Our findings highlight the importance of precise regulation of WASP in hematopoietic development and function, as impairment versus enhancement of its activity give rise to distinct spectra of cellular defects and clinical phenotypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11242115     DOI: 10.1038/85886

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  120 in total

Review 1.  Actin-based motility of intracellular microbial pathogens.

Authors:  M B Goldberg
Journal:  Microbiol Mol Biol Rev       Date:  2001-12       Impact factor: 11.056

Review 2.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Disease models for every field: workshop on the molecular basis of human congenital lymphocyte disorders.

Authors:  C I Edvard Smith
Journal:  EMBO Rep       Date:  2002-06       Impact factor: 8.807

Review 4.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

Review 5.  Wiskott-Aldrich syndrome: another piece in the puzzle.

Authors:  L D Notarangelo; L Mori
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

6.  Wiskott-Aldrich syndrome protein is involved in alphaIIb beta3-mediated cell adhesion.

Authors:  Shigeru Tsuboi; Shigeaki Nonoyama; Hans D Ochs
Journal:  EMBO Rep       Date:  2006-03-31       Impact factor: 8.807

Review 7.  Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?

Authors:  Alejandro A Schäffer; Christoph Klein
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-12

8.  Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia.

Authors:  Jun Xia; Audrey A Bolyard; Elin Rodger; Steve Stein; Andrew A Aprikyan; David C Dale; Daniel C Link
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

9.  Hierarchical regulation of WASP/WAVE proteins.

Authors:  Shae B Padrick; Hui-Chun Cheng; Ayman M Ismail; Sanjay C Panchal; Lynda K Doolittle; Soyeon Kim; Brian M Skehan; Junko Umetani; Chad A Brautigam; John M Leong; Michael K Rosen
Journal:  Mol Cell       Date:  2008-11-07       Impact factor: 17.970

10.  Growth factor independence 1 (Gfi1) regulates cell-fate decision of a bipotential granulocytic-monocytic precursor defined by expression of Gfi1 and CD48.

Authors:  Lothar Vassen; Ulrich Dührsen; Christian Kosan; Hui Zeng; Tarik Möröy
Journal:  Am J Blood Res       Date:  2012-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.